Fig 1.
Flow diagram.
Table 1.
Open-label therapeutic trials of biologics in primary Sjögren’s disease reported between 2002 and 2014.
Table 2.
Controlled therapeutic trials of biologics in primary Sjögren’s syndrome reported between 2002 and 2014.
Fig 2.
Number of patients in the ASSESS cohort fulfilling each inclusion criteria set.
First step: AECG criteria. Second step: systemic disease (ESSDAIhigher to 2). Third step: disease duration less than 4 years. Fourth step: More than two VAS/3 higher to 50/100 mm. Fifth step: biological activity (pSS, primary Sjögren’s syndrome; AECG, American-European Consensus Group; ESSDAI, EULAR Sjögren Syndrome Disease Activity Index; VAS, visual analog scale (100-mm line); BA, biological activity).
Table 3.
Number of patients to include in future randomised controlled trials of rituximab in primary Sjögren’s syndrome according to the primary endpoint assessed at weeks 6, 16, and 24.